<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004057</url>
  </required_header>
  <id_info>
    <org_study_id>98-116</org_study_id>
    <secondary_id>CDR0000067254</secondary_id>
    <secondary_id>MERCK-003-04</secondary_id>
    <secondary_id>NCI-G99-1572</secondary_id>
    <nct_id>NCT00004057</nct_id>
  </id_info>
  <brief_title>Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas</brief_title>
  <official_title>A Phase I and Pharmacokinetic Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of Combination Therapy With Paclitaxel and L-778,123 in Patients With Recurrent or Refractory Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining paclitaxel and L-778,123 in&#xD;
      treating patients who have recurrent or refractory solid tumors or lymphomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of L-778,123 when combined with&#xD;
      paclitaxel in patients with recurrent or refractory solid tumors or lymphomas. II. Evaluate&#xD;
      the safety, tolerability, and dose limiting toxicity of this regimen in these patients. III.&#xD;
      Assess steady state plasma concentrations of various doses of L-778,123 combined with&#xD;
      paclitaxel in these patients. IV. Evaluate radiologic or tumor marker responses to this&#xD;
      regimen in these patients. V. Evaluate the relationship between ras mutations and response to&#xD;
      this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation, multicenter study of L-778,123. Patients receive&#xD;
      paclitaxel IV over 3 hours followed within 24 hours by L-778,123 IV over 7 days. Courses&#xD;
      repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      achieving complete response receive 2 courses after documentation of response. Cohorts of 1-3&#xD;
      patients receive escalating doses of L-778,123 until the maximum tolerated dose (MTD) is&#xD;
      determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting&#xD;
      toxicity. Patients are followed at about 2 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1998</start_date>
  <completion_date type="Actual">December 2000</completion_date>
  <primary_completion_date type="Actual">December 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-778,123</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven solid tumor or lymphoma that is recurrent or&#xD;
        refractory to standard first line therapy Measurable or evaluable disease No active or&#xD;
        inactive primary CNS malignancy No untreated active metastatic CNS malignancy No leukemia&#xD;
        or plasma cell dyscrasias&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:&#xD;
        Greater than 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet&#xD;
        count at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin no greater than&#xD;
        1.5 times normal ALT or AST no greater than 2.5 times normal Alkaline phosphatase no&#xD;
        greater than 4 times normal (no greater than 2 times normal if an increase of greater than&#xD;
        25% over past 2 weeks) PT, INR, or aPTT no greater than 1.2 times normal Renal: Creatinine&#xD;
        no greater than 1.5 times normal Electrolytes within 10% of normal range Cardiovascular: No&#xD;
        prior grade 3 or 4 cardiac arrhythmias except atrial fibrillation No QTc interval of 440&#xD;
        milliseconds or greater on electrocardiogram No other QTc abnormalities No myocardial&#xD;
        infarction, unstable angina, or congestive heart failure within the past 12 months&#xD;
        Psychiatric: No mental or legal incapacitation No concurrent significant emotional problems&#xD;
        No prior psychiatric disorder Neurologic: No grade 2 or higher peripheral neuropathy No&#xD;
        prior seizure disorder Other: Not pregnant or nursing Negative pregnancy test Fertile&#xD;
        patients must use effective double barrier contraception or practice abstinence for at&#xD;
        least 14 days before, during, and for at least 14 days after therapy No allergy to latex,&#xD;
        Cremophor (found in formulations of cyclosporine or vitamin K), or paclitaxel HIV negative&#xD;
        No HIV related malignancy No active infection No prior significant retinal disorder or&#xD;
        disease At least 5 years since prior drug or alcohol abuse&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy No&#xD;
        concurrent immunotherapy No concurrent colony stimulating factors or epoetin alfa&#xD;
        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for mitomycin and&#xD;
        nitrosoureas) At least 4 weeks since prior paclitaxel and recovered No prior high dose&#xD;
        chemotherapy with stem cell rescue No other concurrent chemotherapy Endocrine therapy: At&#xD;
        least 4 weeks since prior endocrine therapy (except chronic LHRH agonist replacement&#xD;
        therapy administered for at least 3 months) No concurrent endocrine therapy except&#xD;
        prophylactic steroids during first course of chemotherapy Radiotherapy: At least 4 weeks&#xD;
        since prior radiotherapy No concurrent radiotherapy Surgery: At least 4 weeks since prior&#xD;
        surgery No concurrent surgery Permanent indwelling central venous catheter required Other:&#xD;
        At least 4 weeks since prior investigational agents (including FDA approved drugs for&#xD;
        non-FDA approved indication) No concurrent medications that prolong QTc interval (e.g.,&#xD;
        terfenadine, astemizole, cisapride, quinidine, procainamide, disopyramide, sotalol,&#xD;
        probucol, bepridil, tricyclic antidepressants, haloperidol, risperidone, indapamide, and&#xD;
        dolasetron mesylate) No concurrent potent inducers of CYP3A (e.g., rifampin, phenobarbital,&#xD;
        phenytoin, carbamazepine, troglitazone, and rifabutin) No concurrent benzodiazepines that&#xD;
        are metabolized by CYP3A (e.g., triazolam, alprazolam, and midazolam) No concurrent HMG-CoA&#xD;
        reductase inhibitors that are metabolized by CYP3A No other prophylactic medications during&#xD;
        first course of chemotherapy except antihistamines and H2 antagonists (for paclitaxel) No&#xD;
        more than 6 cups of coffee or the equivalent for other caffeinated beverages per day At&#xD;
        least 24 hours since prior alcohol consumption No alcohol consumption while confined to the&#xD;
        clinical research unit No more than 24 ounces of beer, 8 ounces of wine, or 3 ounces of&#xD;
        whiskey or other equivalent hard liquor per day while not confined to the clinical research&#xD;
        unit No concurrent illicit drugs No concurrent prochlorperazine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Spriggs, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>September 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2004</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

